Onconova Therapeutics' stock price plummeted by more than 70% Monday morning after the company announced disappointing results from late-stage testing of its lead new drug candidate.
Where can I buy Onconova Therapeutics stock?
Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Onconova Therapeutics' stock price today? One share of ONTX stock can currently be purchased for approximately $1.76.
What is Onconova’s transfer agent?
Onconova’s transfer agent, EQ Shareowner Services, will provide instructions to stockholders of record regarding the process for exchanging share certificates and all book-entry or other electronic positions representing issued and outstanding shares of Onconova common stock will be automatically adjusted.
How does the reverse stock split work at Onconova?
Upon effectiveness of the reverse stock split, each fifteen shares of Onconova’s common stock, par value of $0.01 per share, issued and outstanding immediately prior to the effective time automatically were reclassified, combined, converted and changed into one fully paid and non-assessable share of common stock, par value of $0.01 per share.
Is onconova a good stock to buy?
Onconova Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
What is going on with ONTX stock?
Onconova Therapeutics Inc (NASDAQ:ONTX) The 3 analysts offering 12-month price forecasts for Onconova Therapeutics Inc have a median target of 11.00, with a high estimate of 12.00 and a low estimate of 7.00. The median estimate represents a +856.52% increase from the last price of 1.15.
When did ONTX do a reverse split?
May 20, 2021(Nasdaq: ONTX) (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced a one-for-fifteen reverse stock split of its common stock, effective May 20, 2021.
Is ONTX a decent stock?
The financial health and growth prospects of ONTX, demonstrate its potential to underperform the market. It currently has a Growth Score of F. Recent price changes and earnings estimate revisions indicate this would not be a good stock for momentum investors with a Momentum Score of D.
Is frequency Therapeutics a good stock to buy?
Is FREQUENCY THERAPEUTICS Stock a good buy in 2022, according to Wall Street analysts? The consensus among 2 Wall Street analysts covering (NASDAQ: FREQ) stock is to Buy FREQ stock.
Is ORTX a good stock to buy?
Out of 4 analysts, 1 (25%) are recommending ORTX as a Strong Buy, 1 (25%) are recommending ORTX as a Buy, 1 (25%) are recommending ORTX as a Hold, 0 (0%) are recommending ORTX as a Sell, and 1 (25%) are recommending ORTX as a Strong Sell. What is ORTX's earnings growth forecast for 2022-2024?
What is a 1 for 15 reverse stock split?
In a 1-for-15 reverse stock split, each 100 shares previously purchased is now 7 shares. This split will require some changes to how you continue the Snider Investment Method® in this position.
What does onconova therapeutics do?
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.
1 ONTX Stock's Price Graph & Average Annual Return
Below is a graph showing closing prices of Onconova Therapeutics Inc (ONTX) for the past 10 years. The below chart uses adjusted close instead of market close prices. (Adjusted close factors in corporate or institutional level actions outside the market.)
2 How Onconova Therapeutics Inc (ONTX) Stock Performed Against The Entire Stock Market
You should not evaluate a stock in isolation. Rather, you will benefit more if you assess the performance against broad indices and similar stocks.
4 10 Biggest One-Day Losses
Let us now see 10 biggest one-day losses of Onconova Therapeutics Inc (ONTX) stock.
Conclusion
Hopefully, the above report helps you learn about the past ten-year performance of Onconova Therapeutics Inc (ONTX) shares. Kindly use the sections below to suggest corrections or improvements to the report.
Want to become a smart investor?
Netcials reports section helps you with deep insights into the performance of various assets over the years. We are constantly upgrading and updating our reports section. Feel free to access them. Do not forget to leave your feedback.
What is Onconova Therapeutics?
Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer.
Is Onconova's expectations reasonable?
Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements.
Can we expect ONTX to keep growing?
Over the next three years, it seems the consensus view of the 3 analysts covering ONTX is skewed towards the positive sentiment. Since forecasting becomes more difficult further into the future, broker analysts generally project out to around three years.
Next Steps
Future outlook is only one aspect when you’re building an investment case for a stock. For Onconova Therapeutics, I’ve put together three key aspects you should further research:
About Onconova Therapeutics
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E.
Onconova Therapeutics (NASDAQ:ONTX) Frequently Asked Questions
2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last year. There are currently 2 buy ratings for the stock.
How much will Onconova Therapeutics lose in 2021?
Earlier this week, Onconova Therapeutics released its earnings for the first quarter of 2021 and posted a net loss of $4.7 million compared to a net loss of $5.1 million in the same period in 2020. The company’s R&D expense fell from $3.4 million to $1.9 million over the period.
What is Onconova Therapeutics?
Onconova Therapeutics is a clinical-stage biopharmaceutical company that's discovering and developing novel products for cancer patients. It isn't unusual for clinical-stage companies to see massive volatility around the release of trial results or news of drug approval.
What is reverse split on ONTX?
After the split, the total number of outstanding shares of ONTX will fall from around 236.714 million shares to only about 15.781 million. A reverse split is the opposite of a stock split where the company splits its shares to increase the liquidity. In 2020, both Apple and Tesla split their ...
When does a company reverse its stock split?
In contrast, a company does a reverse stock split when its stock falls too low and it faces the risk of delisting. According to the NYSE listing rules, a stock is subject to delisting if the average price in any 30 consecutive trading day is below $1. Article continues below advertisement.
